Publication Details
Publication: Food Chemical News (食品化学新聞), No. 3132
Publication Date: August 20, 2026
Original Language: Japanese
English Translation of the Published Article
The following English text is a faithful translation of the information presented in the original Japanese media article. Statements concerning study outcomes, functions, or market response are presented as reported by the publication and should be read in that context.
Human Clinical Study Presented at Medical Meeting
Toei Shinyaku, a specialist manufacturer of outdoor-cultivated Agaricus, presented the results of a human clinical study on outdoor-cultivated Agaricus KA21 at the 26th Annual Meeting of the Japanese Society of Anti-Aging Medicine. The study investigated the effects of continuous intake of Agaricus KA21 on quality-of-life parameters in middle-aged and older men.
The clinical study was conducted as a randomized, double-blind, crossover trial involving 15 men aged 40 years and older. Participants consumed 800 mg of outdoor-cultivated Agaricus KA21 per day for eight weeks. The article reports that the study produced findings suggesting that Agaricus KA21 may contribute to maintaining quality of life in middle-aged and older men.
Collaborative Research
The research involved collaboration among multiple institutions, including the Faculty of Health Science at Shigakkan University, the National Center for Geriatrics and Gerontology, Gloo LynQ, Leica, D Clinic Shinjuku, the Institute of Natural Medicine at the University of Toyama, and eHealth Clinic Shinjuku.
About Agaricus KA21
The article describes Agaricus KA21 as an outdoor-cultivated Agaricus grown under sunlight in Brazil. It notes that the mushroom contains β-(1→6)-glucan and β-(1→3)-glucan structures as well as vitamins and minerals including vitamin D, calcium, and copper. Toei Shinyaku has conducted research and development on Agaricus KA21 for more than 30 years, with more than 30 international scientific papers reported.
日本語記事概要 / Japanese Summary
食品化学新聞2026年8月20日号で、第26回日本抗加齢医学会総会において発表された露地栽培アガリクスKA21のヒト臨床試験が紹介されました。40歳以上の男性15名を対象とした無作為化二重盲検クロスオーバー試験で、1日800mgを8週間摂取し、中高齢男性のQOLに関する指標を検証した研究です。至学館大学、国立長寿医療研究センター、Dクリニック新宿、富山大学など複数の研究機関との共同研究として紹介されています。
Original Japanese Article (PDF)
The original Japanese article is available in PDF format. Please refer to the original publication for the source article.